The U.S. Food and Drug Administration approved a new non-opioid pain medication developed by the Massachusetts-based company Vertex Pharmaceuticals ... in Providence, Rhode Island, San Diego ...
The U.S. Food and Drug Administration approved a new non-opioid pain medication developed by the Massachusetts-based company ...
Financial giants have made a conspicuous bearish move on Vertex Pharmaceuticals. Our analysis of options history for Vertex Pharmaceuticals (NASDAQ:VRTX) revealed 10 unusual trades. Delving into ...
Vertex Pharmaceuticals (VRTX) ended the recent trading session at $470.37, demonstrating a +1.88% swing from the preceding day's closing price. The stock's change was more than the S&P 500's daily ...
Vertex Pharmaceuticals (VRTX) stock has performed strongly since the turn of the year, gaining 14.6% and vastly outperforming the healthcare sector as a whole. This time last year, the biotech ...
JOSEPH PREZIOSO / AFP via Getty Images Vertex Pharmaceuticals' non-opioid painkiller received approval from the Food and Drug Administration. The drugmaker said the twice-daily pill, Journavx ...
A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug Administration (FDA). The company’s "first-in-class" suzetrigine pain pill ...
In a report released today, Tazeen Ahmad from Bank of America Securities maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report). The company’s shares closed yesterday at ...
Federal officials on Thursday approved a new type of pain drug designed to eliminate the risks of addiction and overdose ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback